|
|
|
|
 |
Aperio Receives FDA Clearance for ER and PR Image Analysis Applications |
| 8/26/2008 @ 7:52 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, has received clearance from the U.S. Food and Drug Administration (FDA) to market the ER and PR image analysis applications available through its patented ScanScope slide scanning system. The FDA-cleared immunohistochemistry (IHC) image analysis applications are intended to be used as an aid to pathologists in detecting and quantifying ER (estrogen receptor) and PR (progesterone receptor) protein expressions from digital slide images created by Aperio’s slide scanning systems.
Aperio’s FDA clearance encompasses the company’s complete digital pathology system, including ScanScope scanners for creating digital slide images from microscope slides, the SpectrumTM digital pathology information management system for managing, viewing, and analyzing digital slides, and the specific image analysis applications which perform the automated scoring of ER and PR breast cancer digital slides.
“The addition of FDA cleared ER/PR image analysis applications to our previously cleared applications for HER2 underscores our commitment to provide clinicians and breast cancer patients with the most comprehensive entire-slide quantitative image analysis panel available anywhere,” stated Dirk Soenksen, CEO of Aperio. “Aimed with these clearances, our customers can now take full advantage of our new digital IHC software to optimize their workflow and streamline reporting, while enjoying the benefits of quantitative image analysis.“
In 2007, Aperio achieved more than 125% sales growth through continued adoption of its digital pathology platform across a wide spectrum of clinical, research and educational applications. Aperio has an installed base of more than 400 systems in 27 countries, including more than two-thirds of the top 15 rated U.S. hospitals, leading academic medical centers and reference laboratories, and two-thirds of the top 15 pharmaceutical companies.
About Aperio
Aperio is digitizing pathology. We provide systems and services for digital pathology, which is an environment for the management and interpretation of pathology information that originates with the digitization of a glass slide. Aperio’s award-winning ScanScope slide scanning systems and Spectrum digital pathology information management software improve the efficiency and quality of pathology services for pathologists and other professionals. Applications include education, remote viewing, archival and retrieval, basic research, and image analysis. Aperio's products are FDA cleared for specific clinical applications, and are intended for research and education use for other applications. For more information, please visit www.aperio.com. |
| BioTech / BioMedical / Medical |
|
|
| |
| Thursday, December 4, 2008 |
 |
|
VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology Posted 9:48 AM PST
Novio Biomedical and VGX Pharmaceuticals to Highlight Recent Advances in Electroporation-Delivered DVA Vaccines at International DNA Vaccines Conference Posted 7:42 AM PST
Applied Biosystems SOLiD System Named Life Science Innovation of the Year Posted 7:41 AM PST
Ambit Biosciences to Unveil Clinical Data from its AC220 AML Trial at American Society for Hematology Annual Conference Posted 7:37 AM PST
Aperio Introduces SecondSlide Digital Slide Sharing Network Posted 7:33 AM PST
|
| |
| Wednesday, December 3, 2008 |
|
|
Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7 in Turkey Posted 7:19 PM PST
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study Posted 7:15 PM PST
Biocept Awarded Accreditation by the College of American Pathologists Posted 7:13 PM PST
Somaxon Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference Posted 7:07 AM PST
|
| |
| Tuesday, December 2, 2008 |
|
|
Quidel Authorizes Additional $25 Million under Stock Repurchase Program Posted 4:02 PM PST
First-Ever Human Trial of DNA-Based Immunotherapy Delivered Using Inovio Biomedical’s Electroporation Technology Shows Safety and Durable Systemic Clinical Response Posted 8:54 AM PST
Applied Biosystems – Part of Life Technologies – Helps China Respond to Melamine Contamination in Dairy Products Posted 8:51 AM PST
Nirvanix Plays Supporting Role in Ooyala’s Scalable Video Management Platform Posted 8:49 AM PST
ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection Posted 8:47 AM PST
Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference Posted 8:25 AM PST
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia Posted 8:24 AM PST
|
| |
| Monday, December 1, 2008 |
|
|
SpectraScience Awarded European Patent for Its Optical Biopsy System for Tissue Diagnosis Posted 4:39 PM PST
Quidel to Present at the 20th Annual Piper Jaffray Healthcare Conference Posted 4:27 PM PST
Next-Generation Noninvasive Diagnostic Technology Shown to Accurately Detect Fetal Down Syndrome in First Trimester of Pregnancy Posted 4:26 PM PST
Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio Posted 4:25 PM PST
Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference Posted 8:49 AM PST
Applied Nanoscience Announces Successful EPA-FIFRA Registration for NanoFense Formulation Posted 8:46 AM PST
Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease Posted 8:45 AM PST
Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial Posted 8:39 AM PST
PURE Bioscience and Ciba Strike New Contract for Natural Antimicrobial Posted 8:36 AM PST
TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects Posted 8:35 AM PST
DexCom Receives CE Mark Approval for the SEVEN Continuous Glucose Monitoring System European Association for the Study of Diabetes (EASD) meeting Piper Jaffray 20th Annual Health Care Conference Posted 8:29 AM PST
|
| |
| Monday, November 24, 2008 |
|
|
Visage Imaging and Viatronix Sign Comprehensive Marketing Agreement for Virtual Colonoscopy Product Posted 4:27 PM PST
New Noninvasive Prenatal Diagnostic Technology Allows Diagnosis of Inherited Diseases Such as Cystic Fibrosis Caused by Single Gene Mutations Posted 4:23 PM PST
Life Technologies to Present at J.P. Morgan Small/Mid Cap Conference Posted 4:22 PM PST
FDA Extends Review of Somaxon Pharmaceuticals’ New Drug Application for Silenor (Doxepin) by up to Three Months Posted 7:44 AM PST
International Stem Cell Corporation Partners with Absorption Systems to Commercialize Human Stem Cell-Derived Corneal Tissue for Drug Testing Posted 7:40 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
